A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)

Phase 1

• Conditions: Obesity Overweight; Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]

• Registration Number: CTIS2022-501106-35-00
• Lead Sponsor: Eli Lilly & Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-11
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

Have obesity, Have overweight with at least one: Obstructive sleep apnea, have high blood pressure, have high cholesterol, have heart disease

Exclusion Criteria

Have type 1 or type 2 diabetes, Have a self-reported change in body weight over 5 kg within 3 months before screening, Have a planned or prior surgery for obesity, Have severe” kidney impairment, Have long-term or short- term inflammation of the pancreas

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified